Recurrent nitrofurantoin-induced giant cell interstitial pneumonia: Case report and literature review  by Lee, Boeun et al.
lable at ScienceDirect
Respiratory Medicine Case Reports 14 (2015) 49e52Contents lists avaiRespiratory Medicine Case Reports
journal homepage: www.elsevier .com/locate/rmcrCase reportRecurrent nitrofurantoin-induced giant cell interstitial pneumonia:
Case report and literature review
Boeun Lee a, *, Arvind Balavenkataraman b, Devang Sanghavi c, Kristin Walter b
a Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA
b Department of Internal Medicine, Saint Joseph Hospital, Presence Health, Chicago, IL, USA





Metals* Corresponding author. 800 Washington Street, T
MA 02111, USA. Tel.: þ1 6176365000; fax: þ1 617636
E-mail address: Blee4@tuftsmedicalcenter.org (B. L
http://dx.doi.org/10.1016/j.rmcr.2015.01.002
2213-0071/© 2015 The Authors. Published by Elseviera b s t r a c t
Giant cell interstitial pneumonia (GIP) is a rare form of chronic interstitial pneumonia typically associ-
ated with hard metal exposure. Only two cases of GIP induced by nitrofurantoin have been reported in
the medical literature. We are reporting a case of recurrent nitrofurantoin-induced GIP. Although
extremely rare, GIP needs to be included in the differential diagnosis in patients with chronic nitro-
furantoin use who present with respiratory illness.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Case report
A 76-year old Caucasian priest with hypothyroidism and recur-
rent urinary tract infections (UTIs) presented to our hospital in 2010
with shortness of breath, a non-productive cough and right-sided
pleuritic chest pain of a few weeks duration. He had a 78 pack-
year history of tobacco use, but quit in 1986. He had no prior his-
tory of asthma, COPD, pneumonia or interstitial lung disease. At
baseline, he was very active and had no limitation to exercise. Upon
presentation to the hospital, he was experiencing shortness of
breath with minimal exertion and reported a 40-pound weight loss
and dysphagia. He reported no fevers, chills, wheezing, palpita-
tions, or joint pain. His medications included levothyroxine, cal-
cium, and nitrofurantoin which he had taken daily for
approximately 15 years for suppression of UTIs. He had no history
of exposure to heavy metals or asbestos. He had a negative PPD test
in the 1960's and had no known exposure to tuberculosis.
On physical examination, the patient appeared uncomfortable
with moderate respiratory distress. Blood pressure was 110/
65 mm Hg, heart rate was 85 beats per minute, temperature 97.3 F.
He was tachypneic with respiratory rate at 30 breaths per minute
and oxygen saturation of 93% at rest on room air. He had dimin-
ished breath sounds bilaterally with dry crackles, more prominent
on the right side. Laboratory studies revealed a normal white bloodufts Medical Center, Boston,
1580.
ee).
Ltd. This is an open access article ucell count of 8.4  109/L (reference range: 4.4e5.7  109/L) with a
normal differential. The chemistry panel was also within normal
range. Erythrocyte sedimentation rate was over 140 mm/h (normal
range: 1e15 mm/h for men). ANA screen was positive, but all other
serologies for rheumatologic disorders were negative, including
anti-double stranded DNA, Rheumatoid Factor, Scl-70, anti-
centromere B, anti-Jo, anti-ribosomal P, anti-RNP, anti-Sm, anti-SS/
A and SS/b and ACE level. Testing for HIV 1&2 and Quantiferon TB
Gold was negative. CXR showed extensive basilar ﬁbrosis, pleural
thickening and possible basilar inﬁltrates (Fig. 1). Chest computed
tomography (CT) scan with intravenous contrast showed severe
ﬁbrotic changes in both lungs, with honeycombing especially at the
lung bases and diffuse pleural wall thickening (Fig. 2).
Nitrofurantoin was stopped on the day of hospital admission.
The patient underwent video-assisted thoracoscopy (VATS) with
lung and pleural biopsy to establish a diagnosis. The routine aerobic
and anaerobic, fungal and mycobacterial cultures from the lung
tissue and pleural ﬂuid were all negative. A biopsy specimen from
left lower lung demonstrated marked interstitial chronic inﬂam-
mation, subpleural interstitial ﬁbrosis and numerous prominent
multi-nucleated giant cells, consistent with Giant Cell Interstitial
Pneumonia (Fig. 3A and B). Since he had no exposure to hard
metals, GIP was determined to be due to chronic nitrofurantoin use.
He was treated with prednisone 60 mg daily and weaned off ste-
roids over the course of 6 months. His dyspnea on exertion grad-
ually resolved and he was weaned off oxygen as an outpatient.
During a visit to pulmonary clinic ﬁve months after his initial
hospitalization he was noted to have no shortness of breath at rest
or with exertion. He was walking 4e5 miles per day and SpO2 wasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest X-ray, (during ﬁrst hospitalization) shows extensive basilar-predominant
ﬁbrosis, pleural thickening and possible pneumonic inﬁltrates in bilateral lower lobes
of the lungs. No previous CXR was available for comparison.
Fig. 3. Histology from VATS lung biopsy reveals A) marked ﬁbrosis and chronic
inﬂammationwith B) giant cell reactions (hematoxylin-eosin, A.25 B.100). An arrow
shows a multi-nucleated giant cell.
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saturation on room air was 93%. His physical exam was normal
other than mild crackles noted at the right lung base. CXR at that
time showed a signiﬁcant decrease in the pulmonary inﬁltrates and
pleural thickening (Fig. 4). Pulmonary Function Testing (PFT) per-
formed soon after hospital discharge showed a severe obstructive
and moderate restrictive ventilatory defect which improved
signiﬁcantly on follow-up PFT performed ﬁve months later (Fig. 6A
and B).
Two and a half years later, after having no further respiratory
complaints, he presented to pulmonary clinic with recurrent fa-
tigue and progressive dyspnea on exertion, which had developed
over a 6-week period. He was found to be tachypneic and hypox-
emic with SpO2 85% upon walking into the ofﬁce. Physical examFig. 2. CT scan of the chest (during ﬁrst hospitalization) shows pleural thickening and
severe ﬁbrotic changes with honeycombing in both lungs.revealed extensive crackles in both lung bases. A hall walk showed
desaturation to 84% at 85 feet of walking. CXR performed that day
showed extensive bilateral interstitial inﬁltrates and opacities
(Fig. 5). On further inquiry, he reported that approximately 6 weeks
prior to the onset of his recurrent dyspnea. a urologist had placed
him back on nitrofurantoin for UTI prophylaxis. Due to the concern
of recurrent GIP caused by nitrofurantion, he was instructed to stop
nitrofurantoin immediately. He was initially treated as an outpa-
tient with Prednisone 60 mg daily and oxygen. However, on follow-
up visit one week later, he was found to be severely dyspneic and
tachypneic. SpO2 while on oxygen 4 L/minute decreased from 97%
at rest to 81% in less than one minute of walking. He had not been
fully complaint with the outpatient steroid regimen prescribed one
week earlier. Hewas directly admitted to the hospital where hewas
treated with high-dose intravenous methylprednisolone 60 mg
intravenously every 6 h initially and oxygen. No additional Chest CT
or lung biopsy was performed as the patient improved with steroid
treatment. Hewas discharged to a nursing home on oxygen 2 L/min
continuously and 6 L/min overnight. He completed another 6-
month taper of Prednisone, starting at 60 mg, as an outpatient.
Although he has been weaned off steroids and does not have
shortness of breath at rest currently, he experiences dyspnea on
exertion and requires 3 L oxygenwith exercise if walkingmore than
three minutes. He now wears a medical allergy band documenting
his allergy to nitrofurantoin.
Fig. 4. Chest X-ray, (4 months after initial hospitalization) shows minimal left sided
pleural effusion and a signiﬁcant decrease in the pulmonary inﬁltrates and pleural
thickening.
Fig. 5. Chest X-ray (during second hospitalization) shows a dramatic increase in
bilateral opacities compared with previous CXR.
Fig. 6. A: PFT performed approximately 2 months after the initial hospitalization shows a sev
DLCO. B: PFT performed approximately 4 months later shows a signiﬁcant improvement wi
and only a mildly reduced DLCO.
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Nitrofurantoin is a synthetic nitrofurane which is active against
many gram-negative bacilli including Eschericia coli [1]. It has been
widely used to treat urinary tract infections for more than 50 years.
It recently became a ﬁrst-line treatment option for acute uncom-
plicated cystitis based on its efﬁcacy, low cost and minimal resis-
tance [2]. Nitrofurantoin is also commonly used for chronic
suppression of recurrent urinary tract infections [3].
Pulmonary adverse reactions to nitrofurantoin have been well
described in the literature. Both acute and chronic manifestations
have been reported [4,5]. Acute pulmonary reactions, which occur
hours to days into a course of nitrofurantoin, aremore common and
typically manifest as an eosinophilic pneumonia or hypersensitivity
reaction [6,7]. Chronic pulmonary reactions to nitrofurantoin,
which occur months to years after daily nitrofurantoin use, present
as interstitial pneumonitis and ﬁbrosis. Chronic reactions have
been associated with advanced age and prolonged use of nitro-
furantoin but a dose-dependent relationship has not been estab-
lished [6].
Giant cell interstitial pneumonia (GIP) is a rare form of chronic
interstitial pneumonia typically associated with hard metal expo-
sure. GIP was ﬁrst designated as a distinct entity by Liebow and
Carrington in 1969 in the histologic classiﬁcation system of idio-
pathic interstitial pneumonias [8]. However, GIP was subsequently
excluded from the American Thoracic Society and the European
Respiratory Society 2002 consensus statements on idiopathic
interstitial pneumonias [9]. Currently GIP is classiﬁed as a pneu-
moconiosis associated with exposure to hard metals, typically co-
balt and tungsten carbide [10]. GIP has also been described in
literature as Hard Metal Disease, Giant Cell Pneumonitis and Cobalt
Lung. The pathogenesis of GIP remains unclear but an autoimmune
mechanism has been suggested [10].
The hallmarks of GIP on lung biopsy are bizarre appearingmulti-
nucleated giant cells, which have been described as cannibalistic,
and centrilobular ﬁbrosis [11]. Interstitial inﬂammation and orga-
nizing pneumonia can also be seen. Advanced GIP lesions present
with ﬁbrosis and honeycombing [12]. On high resolution Chest CT
scans, GIP can present with ground-glass opacities, irregular linear
opacities, small centrilobular nodules and/or honeycombing [13].
While the vast majority of patients with GIP have had a past
exposure to hard metals, there have been case reports of GIP asso-
ciated with viral, mycobacterial, fungal infections and malignancy inere obstructive and a moderate restrictive ventilation defect and moderately decreased
th a mild restrictive ventilatory defect, resolution of the obstructive ventilatory defect
B. Lee et al. / Respiratory Medicine Case Reports 14 (2015) 49e5252patients without hard metal exposure [14]. Only two cases of
nitrofurantoin-associated GIP have been reported in the literature
[15,16]. All three cases, including ours, share the following charac-
teristics: 1) insidious onset and gradually worsening dyspnea
following long-term nitrofurantoin treatment 2) combined mild
obstructive and restrictive patterns on pulmonary function tests 3)
bilateral inﬁltration on imaging and 4) good response to nitro-
furantoin withdrawal and systemic administration of steroids. Our
case report is unique since this lung biopsy proven case of
nitrofurantoin-induced GIP, appears to have recurred approximately
3 years later, just six weeks after the reintroduction of nitrofurantoin.
Conclusion
Our case highlights that GIP can occur in the absence of hard
metal exposure, can be associated with chronic nitrofurantoin use
and can recur if the patient is re-exposed to nitrofurantoin. Early
recognition and prompt discontinuation of nitrofurantoin is the
mainstay of treatment, along with a course of oral steroids. GIP
should be recognized as a potential adverse reaction to nitro-
furantoin, and taken into consideration, especially before
committing to long-term treatment with nitrofurantoin.
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